Write your message
Volume 7, Issue 3 (May - June 2022)                   J Obstet Gynecol Cancer Res 2022, 7(3): 226-229 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Barooti E, Rashidi Fakari F, Darvish S, Tavakoly N. The Comparison of CA125 Levels in the Normal Pregnancy and Threatened Abortion. J Obstet Gynecol Cancer Res. 2022; 7 (3) :226-229
URL: http://jogcr.com/article-1-416-en.html
1- Department of Obstetrics Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Midwifery, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
3- Department of Obstetrics Gynecology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran , darvishsudabeh@gmail.com
Abstract:   (623 Views)

Background & Objective: In pregnancy, the serum level of cancer antigen-125 (CA-125) increases in the first trimester and abortion. However, different studies reported conflicting results about the use of serum CA-125 to determine the prognosis of threatened abortion. In the present study, we try to determine if the measurement of CA-125 level could be used as a predictor of outcome in women with threatened abortion.
Materials & Methods: This prospective case-control study was performed on 58 patients with threatened abortion and 58 healthy pregnant women with a gestational age of fewer than 20 weeks (as the control group). In both groups, serum CA-125 level was measured. The patients were followed to determine who completed the pregnancy period and who eventually miscarried. Finally, the levels of CA-125 in these groups were compared.
Results: The mean age of patients was 28.47 and 27.84 in the case and control groups, respectively; there was no significant statistical difference between the two groups (95% CI: -1.94 to 3.18, P=0.632). Also, there was no significant difference between them for BMI (95% CI: -1.09 to 1.38, P=0.813), gestational age (95% CI: -1.31 to 1.04, P=0.816), and parity (P=0.51). The mean serum level of CA-125 in the control group was 22.51 ± 6.82 IU/mL, and in the threatened abortion group was 27.70 ± 7.50 IU/mL. This difference was statistically significant (P<0.001). Of the patients, 51.72% with threatened abortion continued their pregnancy, and 48.28% eventually miscarried. The mean serum levels of CA-125 were 25.30±6.63 IU/mL and 30.28±7.63 IU/ml in patients who continued the pregnancy and miscarried, respectively (P=0.01).
Conclusion: A single measurement of the maternal CA-125 may be used as an available, inexpensive prognostic test to determine the outcome of threatened abortion. However, a small number of patients is the main limitation of the present study. More studies with a larger sample size are required to accept the role of maternal CA-125 in predicting the outcome of threatened miscarriage.

Full-Text [PDF 179 kb]   (162 Downloads) |   |   Full-Text (HTML)  (138 Views)  
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2021/06/8 | Accepted: 2021/09/29 | Published: 2022/01/12

1. Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. BMJ. 2004;329(7458):152-5. [DOI:10.1136/bmj.329.7458.152] [PMID] [PMCID]
2. Makrydimas G, Sebire N, Lolis D, Vlassis N, Nicolaides KH. Fetal loss following ultrasound diagnosis of a live fetus at 6-10 weeks of gestation. Ultrasound Obstet Gynecol. 2003; 22(4):368-72. [DOI:10.1002/uog.204] [PMID]
3. Johns J, Hyett J, Jauniaux E. Obstetric outcome after threatened miscarriage with and without a hematoma on ultrasound. Obstet Gynecol. 2003;102(3):483-7. [DOI:10.1097/00006250-200309000-00010] [PMID]
4. Al‐Sebai MA, Kingsland CR, Diver M, Hipkin L, McFadyen IR. The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Br J Obstet Gynaecol. 1995;102(5):364-9. [DOI:10.1111/j.1471-0528.1995.tb11286.x] [PMID]
5. Florio P, Luisi S, D'Antona D, Severi FM, Rago G, Petraglia F, et al. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril. 2004;81(2):468-70. [DOI:10.1016/j.fertnstert.2003.08.008] [PMID]
6. La Marca A, Morgante G, De Leo VJ. Human chorionic gonadotropin, thyroid function, and immunological indices in threatened abortion. Obstet Gynecol.1998;92(2):206-11. [DOI:10.1097/00006250-199808000-00010] [PMID]
7. Fiegler P, Katz M, Kaminski K, Rudol G. Clinical value of a single serum CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med. 48(12):982-8.
8. Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, Romer T. Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001; 97(2):168-73. [DOI:10.1016/S0301-2115(00)00533-9]
9. Ghasemian Dizajmehr S, Sheikhhasani S, Mousavi A, Rashidi Fakari F, Saffarieh E, Ghasemian M, et al. Increased CA125 Level in Ovarian Fibroma: Case Report. Iran J Obstet, Gynecol and Infertil. 2020;23(2):112-5.
10. Berek JS. Berek & Novak's Gynecology Essentials: Lippincott Williams & Wilkins; 2020.
11. Check JH, Nowroozi K, Winkel CA, Johnson T, Seefried L. Serum CA 125 levels in early pregnancy and subsequent spontaneous abortion. Obstet Gynecol. 1990;75(5):742-4.
12. Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, et al. Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol. 1989;160(3):563-6. [DOI:10.1016/S0002-9378(89)80027-4]
13. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast Jr RC. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol. 1984;64(5):703-7.
14. Ayaty S, Vahid Roudsari F, Tavassoly F. Ca-125 In Normal Pregnancy And Threatened Abortion. Int J Reproduc Biomed. 2007;5(3):57-0.
15. Yamane Y, Takahashi K, Kitao M. Prognostic potential of serum CA125 and pregnant markers in threatened abortion. Nihon Sanka Fujinka Gakkai zasshi. 1989;41(12):1999-2004.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.